CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 10, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-07-28
DOI
10.3389/fonc.2020.01243
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
- (2020) Deepu Madduri et al. BLOOD
- Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
- (2020) Bai-Yan Wang et al. BLOOD
- Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors
- (2020) Meng Wang et al. BLOOD
- A Bispecific CAR-T Cell Therapy Targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: Updated Results from a Phase 1 Dose-Climbing Trial
- (2020) Chenggong Li et al. BLOOD
- Translational Analysis from CARTITUDE-1, an Ongoing Phase 1b/2 Study of JNJ-4528 BCMA-targeted CAR-T Cell Therapy in Relapsed and/or Refractory Multiple Myeloma (R/R MM), Indicates Preferential Expansion of CD8+ T Cell Central Memory Cell Subset
- (2020) Enrique Zudaire et al. BLOOD
- Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma
- (2020) Chunrui Li et al. BLOOD
- Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma
- (2020) Andrew J. Cowan et al. BLOOD
- Optimal Dual-Targeted CAR Construct Simultaneously Targeting Bcma and GPRC5D Prevents Bcma-Escape Driven Relapse in Multiple Myeloma
- (2020) Carlos Fernandez de Larrea et al. BLOOD
- Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-Bcma CAR T Cell Therapy
- (2020) Jesus G. Berdeja et al. BLOOD
- ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
- (2020) S. Depil et al. NATURE REVIEWS DRUG DISCOVERY
- CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
- (2020) Sabarinath V. Radhakrishnan et al. Nature Communications
- Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
- (2020) Norris Lam et al. Nature Communications
- Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab
- (2020) Estefanía García-Guerrero et al. LEUKEMIA
- Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
- (2020) Eugenia Zah et al. Nature Communications
- GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
- (2019) Eric L. Smith et al. Science Translational Medicine
- CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response
- (2019) Nicholas F. Kuhn et al. CANCER CELL
- The response to lymphodepletion impacts PFS in aggressive non-Hodgkin lymphoma patients treated with CD19 CAR-T cells
- (2019) Alexandre V. Hirayama et al. BLOOD
- Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics
- (2019) Boris Gorovits et al. BIODRUGS
- CAR-T efficacy: is conditioning the key?
- (2019) Sattva S. Neelapu BLOOD
- Phase 2 study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma, the carthadex trial
- (2019) Ruth Wester et al. HAEMATOLOGICA
- B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
- (2019) Adam D. Cohen et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
- (2019) Jie Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy
- (2019) Eric L. Smith et al. Cancer Immunology Research
- Managing the toxicities of CAR T‐cell therapy
- (2019) Sattva S. Neelapu HEMATOLOGICAL ONCOLOGY
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study
- (2019) Philippe Moreau et al. LANCET
- Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells
- (2019) Haiming Chen et al. LEUKEMIA RESEARCH
- The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
- (2019) Katrin Mestermann et al. Science Translational Medicine
- Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T
- (2019) Thomas Nerreter et al. Nature Communications
- γ-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma
- (2019) Margot J. Pont et al. BLOOD
- Multispecific targeting with synthetic ankyrin repeat motif chimeric antigen receptors
- (2019) Ashwini Balakrishnan et al. CLINICAL CANCER RESEARCH
- Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide
- (2019) Melissa Works et al. MOLECULAR CANCER THERAPEUTICS
- Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)
- (2019) Caitlin L. Costello et al. BLOOD
- T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain Induce Remissions in Patients with Relapsed Multiple Myeloma
- (2019) Lekha Mikkilineni et al. BLOOD
- Manufacture of an Allogeneic CAR-T Stem Cell Memory Product Candidate for Multiple Myeloma, P-Bcma-ALLO1, Is Robust, Reproducible and Highly Scalable
- (2019) Stacey A Cranert et al. BLOOD
- Phase 1 First-in-Human Study of AUTO2, the First Chimeric Antigen Receptor (CAR) T Cell Targeting APRIL for Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
- (2019) Rakesh Popat et al. BLOOD
- B Cell Maturation Antigen-Specific CAR T Cells for Relapsed or Refractory Multiple Myeloma: A Meta-Analysis
- (2019) Nico Gagelmann et al. BLOOD
- Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma
- (2019) Jin Jie et al. BLOOD
- Superior Efficacy of CAR-T Cells Using Marrow-Infiltrating Lymphocytes (MILsTM) As Compared to Peripheral Blood Lymphocytes (PBLs)
- (2019) Eric R. Lutz et al. BLOOD
- Development of an Allogeneic Anti-Bcma T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure
- (2019) Bei Bei Ding et al. BLOOD
- A Bcma and CD19 Bispecific CAR-T for Relapsed and Refractory Multiple Myeloma
- (2019) Hua Zhang et al. BLOOD
- Management of adults and children undergoing CAR t-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
- (2019) Ibrahim Yakoub-Agha et al. HAEMATOLOGICA
- CD56–chimeric antigen receptor T-cell therapy for refractory/recurrent rhabdomyosarcoma
- (2019) Chiyi Jiang et al. MEDICINE
- A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial
- (2019) Zhiling Yan et al. Lancet Haematology
- B cell maturation antigen‐specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta‐analysis
- (2019) Nico Gagelmann et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Effective Targeting of Multiple B-Cell Maturation Antigen–Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells
- (2018) Kevin M. Friedman et al. HUMAN GENE THERAPY
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells
- (2018) Wenting Zheng et al. LEUKEMIA
- Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector
- (2018) Eric L. Smith et al. MOLECULAR THERAPY
- Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
- (2018) Margherita Norelli et al. NATURE MEDICINE
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
- (2018) Joseph A. Fraietta et al. NATURE MEDICINE
- CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
- (2018) Theodoros Giavridis et al. NATURE MEDICINE
- Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
- (2018) David T. Teachey et al. Nature Reviews Clinical Oncology
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome
- (2018) Robert Q. Le et al. ONCOLOGIST
- Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design
- (2018) Esther Drent et al. PLoS One
- Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL)
- (2018) Bianca D. Santomasso et al. Cancer Discovery
- Chimeric Antigen Receptor T Cell–Mediated Neurotoxicity in Nonhuman Primates
- (2018) Agne Taraseviciute et al. Cancer Discovery
- Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma
- (2018) De-Xiu Bu et al. Oncotarget
- Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene
- (2018) Monica Casucci et al. Frontiers in Immunology
- Cytokine release syndrome
- (2018) Alexander Shimabukuro-Vornhagen et al. Journal for ImmunoTherapy of Cancer
- A Phase I Study to Assess the Safety and Pharmacokinetics of Single-Agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56 Positive Multiple Myeloma
- (2018) Sikander Ailawadhi et al. Clinical Lymphoma Myeloma & Leukemia
- Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia
- (2018) John K. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Strategies to Address Chimeric Antigen Receptor Tonic Signaling
- (2018) Adam Ajina et al. MOLECULAR CANCER THERAPEUTICS
- Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
- (2018) Joseph A. Fraietta et al. NATURE
- Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
- (2018) Sarwish Rafiq et al. NATURE BIOTECHNOLOGY
- Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
- (2018) Kris M. Mahadeo et al. Nature Reviews Clinical Oncology
- Tumor Antigen Escape from CAR T-cell Therapy
- (2018) Robbie G. Majzner et al. Cancer Discovery
- Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy
- (2018) Noelle Frey et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
- (2018) Jennifer N. Brudno et al. BLOOD REVIEWS
- A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
- (2018) Wan-Hong Zhao et al. Journal of Hematology & Oncology
- Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
- (2018) Susanne H. Baumeister et al. Cancer Immunology Research
- Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
- (2018) Kerry S. Campbell et al. Frontiers in Immunology
- Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance
- (2017) Sophia Danhof et al. HAEMATOLOGICA
- Chimeric antigen receptor transduced T cells: Tuning up for the next generation
- (2017) Maria-Luisa Schubert et al. INTERNATIONAL JOURNAL OF CANCER
- A compound chimeric antigen receptor strategy for targeting multiple myeloma
- (2017) K H Chen et al. LEUKEMIA
- A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization
- (2017) Esther Drent et al. MOLECULAR THERAPY
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
- (2017) Justin Eyquem et al. NATURE
- SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin
- (2017) Jun Chen et al. NATURE
- The activated conformation of integrin β7 is a novel multiple myeloma–specific target for CAR T cell therapy
- (2017) Naoki Hosen et al. NATURE MEDICINE
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
- (2017) Juliane Gust et al. Cancer Discovery
- Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent
- (2017) Diogo Gomes-Silva et al. Cell Reports
- Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance
- (2017) Sophia Danhof et al. HAEMATOLOGICA
- Multiple myeloma
- (2017) Shaji K. Kumar et al. Nature Reviews Disease Primers
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment
- (2016) Y.-T. Tai et al. BLOOD
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma
- (2016) E. Sanchez et al. CLINICAL CANCER RESEARCH
- The urgent need to recover MHC class I in cancers for effective immunotherapy
- (2016) Federico Garrido et al. CURRENT OPINION IN IMMUNOLOGY
- Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
- (2016) E. Drent et al. HAEMATOLOGICA
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
- (2016) Michael Ghermezi et al. HAEMATOLOGICA
- Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
- (2016) Carlos A. Ramos et al. JOURNAL OF CLINICAL INVESTIGATION
- Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors
- (2016) R Monjezi et al. LEUKEMIA
- Differentiation stage of myeloma plasma cells: biological and clinical significance
- (2016) B Paiva et al. LEUKEMIA
- Multiple myeloma causes clonal T-cell immunosenescence: identification of potential novel targets for promoting tumour immunity and implications for checkpoint blockade
- (2016) H Suen et al. LEUKEMIA
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
- (2016) E. Drent et al. HAEMATOLOGICA
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
- (2016) Michael Ghermezi et al. HAEMATOLOGICA
- Marrow-Infiltrating Lymphocytes – Role in Biology and Cancer Therapy
- (2016) Ivan Borrello et al. Frontiers in Immunology
- Fine-tuning the CAR spacer improves T-cell potency
- (2016) Norihiro Watanabe et al. OncoImmunology
- Toxicity and management in CAR T-cell therapy
- (2016) Challice L Bonifant et al. Molecular Therapy-Oncolytics
- Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies
- (2015) Laurent Poirot et al. CANCER RESEARCH
- Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
- (2015) I S Nijhof et al. LEUKEMIA
- Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
- (2015) D Sommermeyer et al. LEUKEMIA
- Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma
- (2015) Andrew T. Hutchinson et al. MOLECULAR IMMUNOLOGY
- NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
- (2015) Aaron P Rapoport et al. NATURE MEDICINE
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
- (2015) Alfred L. Garfall et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- γ-secretase directly sheds the survival receptor BCMA from plasma cells
- (2015) Sarah A. Laurent et al. Nature Communications
- CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma
- (2015) Sara Yousef et al. Human Vaccines & Immunotherapeutics
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- Robust isolation of malignant plasma cells in multiple myeloma
- (2014) I. Frigyesi et al. BLOOD
- Cutting Edge: The Dependence of Plasma Cells and Independence of Memory B Cells on BAFF and APRIL
- (2014) M. J. Benson et al. JOURNAL OF IMMUNOLOGY
- The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
- (2014) M. Hudecek et al. Cancer Immunology Research
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- GPRC5D is a promising marker for monitoring the tumor load and to target multiple myeloma cells
- (2013) Yossi Cohen et al. Hematology
- Chemotherapy stimulates syndecan-1 shedding: A potentially negative effect of treatment that may promote tumor relapse
- (2013) Vishnu C. Ramani et al. MATRIX BIOLOGY
- Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
- (2013) Cor HJ Lamers et al. MOLECULAR THERAPY
- Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
- (2012) Eric Sanchez et al. BRITISH JOURNAL OF HAEMATOLOGY
- Abstract 3499: CD56 targeted chimeric antigen receptors for immunotherapy of multiple myeloma
- (2012) Reuben Benjamin et al. CANCER RESEARCH
- Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma
- (2012) Johanna Atamaniuk et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma
- (2012) P C Schuberth et al. GENE THERAPY
- Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide
- (2012) YAWARA KAWANO et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
- (2012) J. Scholler et al. Science Translational Medicine
- Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells
- (2011) A Barber et al. GENE THERAPY
- Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease
- (2011) Robert C. Rickert et al. IMMUNOLOGICAL REVIEWS
- Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
- (2010) Michael C. Jensen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen
- (2010) S Peinert et al. GENE THERAPY
- Expression of SLAM (CD150) cell-surface receptors on human B-cell subsets: From pro-B to plasma cells
- (2010) Jose De Salort et al. IMMUNOLOGY LETTERS
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- SLAM-Family Receptors: Immune Regulators with or without SAP-Family Adaptors
- (2010) A. Veillette Cold Spring Harbor Perspectives in Biology
- Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
- (2009) L. A. Johnson et al. BLOOD
- APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop
- (2009) Jérôme Moreaux et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
- (2009) Michael C. Milone et al. MOLECULAR THERAPY
- APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells
- (2008) E. Belnoue et al. BLOOD
- Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance
- (2008) W. Matsui et al. CANCER RESEARCH
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
- Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
- (2008) Salima Hacein-Bey-Abina et al. JOURNAL OF CLINICAL INVESTIGATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started